辉瑞为提出IBRANCE这样的创新疗法而自豪。” 临床3期招募521位患者。IBRANCE的警告和注意事项包括中性粒细胞减少、肺栓塞和胚胎胎儿毒性。 http://.pharmacodia/ 相关阅读: PfizerReceivesExpandedFDAApprovalForIBRANCE(palbociclib)InHR+, HER2-MetastaticBreastCancer ...
Nearly 10,000 women filed Prempro breast cancer lawsuits against Pfizer. By 2012, Pfizer settled most of the claims for more than $1 billion. Chantix About 3,000 people filed Chantix lawsuits against Pfizer. They claimed Chantix caused suicidal thoughts and severe psychological disorders. In 2013...
We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to ...
Pfizer is a biopharmaceutical company involved in the discovery, development, and delivery of medicines and vaccines. The company provides products and services including vaccines, gene therapy, and treatments for diseases such as cancer, inflammation, and infectious diseases. Pfizer serves sectors includi...
(NYSE: TMO) today announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where a...
cancer (la/mUC); and the first data combining atirmociclib, our highly-selective cyclin-dependent kinase 4 (CDK4) inhibitor (CDK4i), with a novel CDK2 inhibitor (CDK2i) in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC) from a Phase 1 dose-escalation s...
Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved IBRANCE® (palbociclib) 125mg for an expanded indication, to treat metastatic breast cancer. IBRANCE is also approved in combination with AstraZeneca's (AZ) endocrine therapy drug Faslodex (fulvestrant,...
Breast Cancer: As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. ...
Cancer Type Phase Filters Breast Cancer Atirmociclib (PF-07220060) CDK4 Inhibitor Phase 1 Phase 2 Phase 3 KAT6 Inhibitor + Atirmociclib (PF-07220060) PF-07248144CDK4 Inhibitor Phase 1 Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Atirmociclib (PF-07220060) ...
Target Indications: Treatment of HER2-overexpressing breast cancer and and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinomaDeveloped and marketed by PfizerSummary: Trazimera is a biosimilar version of trastuzumab (reference product, Herceptin, Roche, Inc.) developed by Pfizer...